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Abstract
Background: Endothelial dysfunction is considered an early step of atherosclerotic vascular disease. Asymmetric
dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase (NOS), plays a critical role in the
process of atherosclerosis in a uremic environment. Increased plasma ADMA not only works as a cardiovascular
morbidity biomarker but it is also involved in the genesis of atherosclerosis in renal disease. Considering the
relationships of apolipoprotein E(ApoE) polymorphism with LDL cholesterol (LDL-C) levels and coronary risk, it is
possible that it brings on susceptibility to endothelial dysfunction and atherogenesis seen on uremia.
Methods: Six hundred twenty patients were stratified according to glomerular filtration rate (GFR) estimated by
Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) formula: group I > 60 mL/min, group II≤ 60 mL/min
and > 15 mL/min, and group III ≤ 15 mL/min or in hemodialysis. Polymorphic ApoE analysis was performed by
polymerase chain reaction amplification (PCR). Plasma ADMA levels were measured by high performance liquid
chromatography (HPLC). Groups were compared on clinical and laboratory characteristics as well as allele and
genotype distribution towards.
Results: The ε2 allele of ApoE was present in 62 (10.3 %) patients, ε3 allele in 581 (96.2 %), and ε4 allele in 114
(18.9 %). Their distribution among the 3 groups was uniform. Such uniformity was not observed when we
considered endothelial function measured by asymmetric dimethylarginine. In group III, the frequency of ε4 allele
was significantly lower in the third tertile compared with the first tertile (14.7 versus 53.3 %, P = 0.000; Pearson chi-
square). In groups I and II, there was no difference in allele frequency according to ADMA levels. This association
remained significant even after confouding factors corrections (OR 0.329, 95 % CI 0.155 - 0.699, P = 0.004).
Conclusions: The results of this study shows that the frequency of ε4 allele of ApoE is significantly lower among
hypertensive patients on hemodialysis with the highest levels of ADMA. Uremia is capable of determining lower
plasma ADMA levels in hypertensive ε4 allele carriers.
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Background
As stated in the 2014 United States Renal Data System
Annual Data Report, the burden of cardiovascular disease
(CVD) in chronic kidney disease (CKD) is still consider-
able, where CVD in CKD individuals is 2–3 more frequent
when compared with the general population. There is a
stepwise decrease in survival related to advanced CKD
stage, and mortality after congestive heart failure (CHF) or
myocardial infarction (MI) in patients with stages 4–5
CKD is similar to that of dialysis patients [1].
It was first reported in 1992 that nitric oxide (NO)
synthesis can be inhibited by ADMA, which is substan-
tially elevated in plasma of patients on hemodialysis. It
was suggested that the accumulation of ADMA and con-
comitant inhibition of NO synthesis may contribute to
hypertension, immune dysfunction, and CVD in these
patients [2]. ADMA, as the main endogenous inhibitor
of NOS, plays a critical role in the process of athero-
sclerosis in a uremic environment [3]. Endothelial
dysfunction resulting from reduced NO activity is con-
sidered an early step of atherosclerotic vascular disease
[4]. Increased plasma ADMA concentrations not only
works as a cardiovascular morbidity biomarker but is
causally involved in the genesis of atherosclerosis in
renal disease [5–7].
Also related to atherosclerosis, ApoE is a multifunc-
tional protein that plays a major role in the metabolism of
cholesterol and triglycerides by binding to receptors in the
liver to help mediate the clearance of chylomicrons and
very low-density lipoproteins from the bloodstream. ApoE
polymorphism is also implicated in the burden of CVD.
Boerwinkle et al. reported that up to 17 % of the genetic
variability in total plasma cholesterol may be attributable
to the ApoE polymorphism [8].
Since ApoE polymorphism is a key player in lipid me-
tabolism, it is possible that it leads to susceptibility to
endothelial dysfunction and atherogenesis. Aim of study
was to evaluate the interaction between ADMA levels
and ApoE polymorphism in patients stratified according
3 different degrees of renal function.
Results
Demographic and laboratory characteristics of the
patients are summarized in Table 1. Eight subjects were
excluded because of missing ApoE polymorphism data,
leaving 612 subjects for analysis. Mean age of the pa-
tients was 60.1 ± 14.1 years, 311 (50.7 %) were male,
mean body mass index (BMI) was 28.0 ± 5.3, 386
(63.2 %) were Caucasians, 238 (38.9 %) had Diabetes
Mellitus (DM), and 218 (35.6 %) had CVD. Groups I, II
Table 1 Demographic and laboratory characteristics of patients stratified by renal function
Group I(N = 189) Group II(N = 222) Group III(N = 202) p
Age (years) 60.0 ± 11.7 66.8 ± 11.6 52.4 ± 14.9 0.000**
Male 57 (30.5 %) 136 (61.3 %) 117 (58.2 %) 0.000***
Caucasian 105 (56.1 %) 145 (65.9 %) 138 (68.9 %) 0.000***
BMI (kg/cm2) 30.3 ± 6.2 28.6 ± 5.1 25.2 ± 2.6 0.000**
Waist circumference (cm) 98.3 ± 13.9 101.9 ± 13.5 95.6 ± 10.8a 0.004*
Diabetes mellitus 59 (32.6 %) 118 (53.4 %) 65 (32.5 %) 0.000***
Metabolic Syndrome 118 (64.1 %) 158 (71.8 %) 146 (73.0 %) 0.000***
Cardiovascular Disease 44 (24.6 %) 91 (41.9 %) 86 (43.7 %) <.000***
o Cerebrovascular disease 20 (11.2 %) 26 (12.0 %) 21 (10.7 %) 0.912***
o Coronary disease 17 (9.5 %) 51 (23.5 %) 44 (22.3 %) 0.001***
o Peripheral vascular disease 11 (6.1 %) 18.9 (41.0 %) 46 (23.4 %) 0.000***
o Congestive heart failure 17 (9.5 %) 33 (15.3 %) 31 (15.7 %) 0.000***
Statin use 77/181 (40.7 %) 125/222 (54.3 %) 107/200 (53.2 %) 0.017***
Cholesterol(mM) 4.78 ± 0.93 4.65 ± 1.12 3.72 ± 1.00a.b 0.000*
HDL-C(mM) 1.27 ± 0.34 1.16 ± 0.33c 0.99 ± 0.37 a.b 0.000*
LDL-C(mM) 2.78 ± 0.82 2.64 ± 0.97 1.89 ± 0.74a.b 0.000*
Triglycerides(mM) 1.61 ± 0.90 1.80 ± 0.98 1.91 ± 1.31 0.023**
Creatinine(μM) 73.4 ± 15.9 175.0 ± 69.8 930.8 ± 284.6 0.000**
ADMA (μM) 0.48 ± 0.12 0.75 ± 0.31a 1.34 ± 0.90 0.000**
CRP (mg/dL) 0.49 ± 0.73 0.62 ± 0.83 1.47 ± 3.78 0.004**
*ANOVA, **Kruskal-Wallis-one way- ANOVA, ***Pearson chi-square
By post hoc Bonferroni test: agroups III and II, bgroups III and I, cgroups II and I
Marrocos et al. Lipids in Health and Disease  (2016) 15:14 Page 2 of 9
and III were composed respectively of 199, 206 and 207
patients. In comparison with group I, groups II and III
included more males and Caucasians, while group III
had a lower mean age (52.4 ± 14.9 years). Hemodialysis
vintage in group III was 37.36 ± 26.84 months. BMI and
waist circumference decreased from group I to group
III. Prevalence of DM was highest in group II (53.4 %);
metabolic syndrome and CVD increased in prevalence
from group I to group III. Use of statins was predomin-
ate in groups II and III (54.3 % and 53.2 %).
HDL colestherol (HDL-C), LDL-C and triglyceride
concentrations significantly decreased with decrease in
estimated GFR. Plasma concentrations of ADMA and C
reactive protein (CRP) significantly increased with de-
crease in estimated GFR.
The ε2 allele was present in 62 (10.3 %) patients, ε3
allele in 581 (96.2 %), and ε4 allele in 114 (18.9 %). The
ε3/2 genotype was present in 57 (9.3 %) patients, ε3/3
genotype in 438 (71.7 %), ε4/2 genotype in 10 (1.6 %),
ε4/3 genotype in 93 (15.2 %) and ε4/4 genotype in 13
(2.1 %). Table 2 depicts ApoE genotype and allele distri-
bution among the 3 renal function groups. There was
evidence of a significant association (P = 0.018) with
Caucasians for the ε4 allele, when distribution of geno-
types and alleles were stratified by race (Table 3).
Table 4 depicts the statistically significant difference in
plasma ADMA levels between patientes on renal re-
placement therapy (RRT) based on ApoE ε4 allele pres-
ence; Table 5 presents demographic and laboratory
characteristics of patients according to ADMA tertile.
ApoEε4 allele predominated in the first tertil of ADMA
(Table 6). As also shown in Fig. 1, in group III, the
frequency of ε4 allele of ApoE was significantly lower in
the third tertile of ADMA compared with the first ter-
tile. In groups I and II, there was no difference in allele
frequency according to ADMA level. This association
remained significant even after controlling for
confounders (OR 0.329,95 % CI 0.155 – 0.699; P =
0.004), namely age, sex, BMI, DM, CVD, CRP, LDL-C
and dialysis vintage (Table 7).
Analyses of clinical and laboratory characteristics of ε2
and ε3 alllele carriers showed no statistical difference
between allele (+) versus allele (−) groups and stratified
for RRT allocation or not (data not shown).
Discussion
According to the literature, our data confirm that
increased plasma ADMA levels are associated with
decreasing GFR. We did not identify a difference in the
distribution of ApoE genotypes and alleles between
groups, but among patients on hemodialysis and with
highest ADMA levels, the frequency of ε4 allele of ApoE
was significantly lower when compared with that in pa-
tients in the first ADMA tertile. The observed difference
did not occur in patients with normal renal function or
in earlier stages of CKD.
In fact, ADMA levels are intrinsically related with
renal function and this association has been studied in
the past few years. The 3 groups in our study showed
progressively higher plasma ADMA levels following the
evolution of CKD. In accordance with our data, Fliser et
al. found that ADMA was significantly associated with
progression of nondiabetic kidney diseases [9]. Ravani et
al. found that in patients with mild CKD plasma ADMA
was inversely proportional to GFR and represented a
strong and independent risk marker for progression to
end stage renal disease (ESRD) and mortality [10]. Ini-
tially, the elevation of ADMA in uremia was credited only
to the decrease in GFR. Thereafter, elevations in plasma
ADMA concentrations were also reported in incipient
renal diseases, such as autosomal-dominant polycystic
kidney disease [11] and IgA nephropathy [12], and in nor-
mal renal function such hypercholesterolemia or athero-
sclerosis [13]. ADMA is renally excreted to some extent,
Table 2 ApoE genotype and allele distribution among the 3
renal function groups
Group I Group II Group III Total P*
N (%) N (%) N (%) N (%)
ε3/ε2 17 (9.3) 19 (8.6) 16 (8.0) 52 (8.6) NS
ε3/ε3 128 (69.9) 167 (75.2) 143 (71.9) 438 (72.5) NS
ε4/ε2 7 (3.8) 1 (0.5) 2 (1.0) 10 (1.7) NS
ε4/ε3 28 (15.3) 30 (13.5) 33 (16.6) 91 (15.1) NS
ε4/ε4 3 (1.6) 5 (2.3) 5 (2.5) 13 (2.2) NS
ε2 allele 24 (13.1) 20 (9.0) 18 (9.0) 62 (10.3) NS
ε3 allele 173 (94.5) 216 (97.3) 192 (96.5) 581 (96.2) NS
ε4 allele 38 (20.8) 36 (16.2) 40 (20.1) 101(18.9) NS
*Pearson chi-square
Table 3 ApoE genotype and allele distribution based on race
Caucasians Afro-Americans Others Total P*
N (%) N (%) N (%) N (%)
ε3/ε2 36 (9.3) 8 (6.5) 10 (10.5) 54 (8.9) NS
ε3/ε3 266 (68.9) 95 (77.2) 74 (77.9) 434 (71.9) NS
ε4/ε2 6 (1.6) 3 (2.4) 1 (1.1) 10 (1.7) NS
ε4/ε3 71 (18.4) 12 (9.8) 10 (9.5) 93 (15.4) NS
ε4/ε4 7 (1.8) 5 (4.1) 1 (1.1) 13 (2.1) NS
ε2 allele 42 (10.9) 11 (8.9) 11 (11.6) 64 (10.6) NS
ε3 allele 373 (96.6) 115 (93.5) 94 (97.9) 582(96.2) NS
ε4 allele 84 (21.8) 20 (16.3) 12 (11.6) 116 (19.2) 0.018
*Pearson chi-square
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but its rise in CKD is due to increased activity of protein
arginine methyltransferases [14], a family of enzymes in-
volved in the process of post-translational methylation of
arginine residues, a common mechanism of protein modi-
fication. In addition, accumulation of ADMA in patients
with CKD is also related to decreased activity of the enzyme
dimethyl arginine dimethyl aminohydrolase (DDAH)
[14], part of the main pathway for ADMA degradation,
which hydrolyzes ADMA to dimethylamine and L‐citrulline.
So far, two isoforms of DDAH have been characterized
and cloned: DDAH I is predominately found in tissues
that express neuronal NOS, whereas DDAH II is pre-
dominately found in tissues expressing endothelial
NOS [14, 15]. It is estimated that healthy humans
produce approximately 300 μmol of ADMA per day, of
which approximately 250 μmol are metabolized by
DDAHs [16].
ADMA is an endogenous inhibitor of nitric oxide
synthases (NOS), which may in part explain the impaired
vasorelaxation, elevated inflammation, and reduced angio-
genesis reported in CKD patients and animal models of
CKD [17]. The role of ADMA in atherogenesis is not
restricted to its inhibitory action on NOS. It upregulates
the expression of acyl-coenzyme A cholesterol acyltrans-
ferase 1 present in macrophages and is implicated in the
formation of foam cells [7]. ADMA also impairs the
migratory capacity of angiogenic progenitor cells (APCs)
in patients with coronary artery disease through a micro
RNA-21-dependent mechanism, inhibiting superoxide dis-
mutase 2 in APCs [18].
Accumulation of ADMA is a risk factor and is causally
related to the development of endothelial dysfunction and
cardiovascular disease in patients with CKD [19–22].
Zoccali et al. demonstrated in patients undergoing
hemodialysis with initially normal carotid intima-media
thickness, that ADMA and CRP are interacting factors in
the progression of carotid intimal lesions [23].
ApoE gene contains three potential alleles: ∈2, ∈3 and
∈4, forming six genotypes and determining diversity in
clinical expression. Allele frequency from high to low is
ε3, ε2 and ε4, and ε3ε3 is the most common phenotype
in humans [24], as seen in our study. In NHANES III
[25], the ε2 allele was the rarest for each ethnicity exam-
ined, and the frequency of the e4 allele was 10.8 %
Table 4 Demographic and laboratory characteristics of patients according to RRT allocation and ApoE ε4 allele presence
In RRT Not in RRT
ε4 allele (+) (N = 40) ε4 allele (−) (N = 158) P ε4 allele (+) (N =74) ε4 allele (−) (N = 330) P
Age (years) 52.47 ± 14.97 53.60 ± 14.36 0.669* 62.80 ± 13.36 63.81 ± 11.72 0.511*
Dialysis vintage 38.95 ± 24.24 37.22 ± 27.69 0.697* - -
Male 25 (21.6 %) 91 (78.4 %) 0.574** 37 (19.7 %) 151 (80.3 %) 0.508**
Caucasian 31 (22.8 %) 105 (72.2 %) 0.403** 51 (20.6 %) 196 (79.4 %) 0.440**
BMI (kg/cm2) 25.15 ± 11.12 25.57 ± 2.44 0.356* 29.17 ± 6.40 29.33 ± 5.61 0.844*
Waist circumference (cm) 97.25 ± 15.96 99.30 ± 9.13 0.283* 99.81 ± 14.73 100.27 ± 13.59 0.798*
Diabetes mellitus 15 (23.1 %) 50 (76.9 %) 0.418** 32 (18.8 %) 138 (81.2 %) 0.895**
Metabolic syndrome 28 (19.4 %) 116 (80.6 %) 0.621** 48 (17.8 %) 222 (82.2 %) 0.733**
Cardiovascular disease 19 (22.6 %) 65 (77.4 %) 0.547** 26 (19.8 %) 105 (80.2 %) 0.653**
o Cerebrovascular disease 0 (0.0 %) 20 (100.0 %) 0.016** 13 (28.3 %) 33 (71.7 %) 0.073**
o Coronary disease 13 (29.5 %) 31 (70.5 %) 0.096** 11 (16.9 %) 54 (83.1 %) 0.703**
o Peripheral vascular disease 9 (20.5 %) 35 (79.5 %) 0.976** 10 (20.4 %) 39 (76.9 %) 0.697**
o Congestive Heart Failure 6 (19.4 %) 25 (80.6 %) 0.850** 7 (14.9 %) 40 (85.1 %) 0.480**
Statin use 23 (21.9 %) 82 (78.1 %) 0.551** 38 (19.4 %) 158 (80.6 %) 0.602**
Cholesterol(mmol/L) 3.75 ± 1.01 3.62 ± 0.90 0.470* 4.58 ± 1.06 4.75 ± 1.06 0.175*
HDL-C(mmol/L) 0.97 ± 0.34 1.08 ± 0.46 0.108* 1.15 ± 0.31 1.22 ± 0.35 0.128*
LDL-C(mmol/L) 1.92 ± 0.74 1.82 ± 0.76 0.469* 2.62 ± 0.85 2.79 ± 0.92 0.151*
Triglycerides(mmol/L) 1.98 ± 1.36 1.66 ± 1.14 0.160* 1.84 ± 1.06 1.69 ± 0.90 0.237*
ADMA (uM) 0.95 ± 0.45 1.44 ± 0.96 0.000* 0.58 ± 0.17 0.63 ± 0.28 0.134*
CRP (mg/dL) 1.67 ± 3.52 1.42 ± 3.88 0.711* 0.50 ± 0.72 0.57 ± 0.76 0.468*
*Student’s t test
**Pearson chi-square
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among Mexican Americans, compared to 15 % in whites
and 22 % in non-Hispanic blacks. Similarly to Chu et al.
[25], we demonstrated that the ε2 allele was the less
prevalent in all groups in our analysis of allele and geno-
type distribution by race. ApoE ε4 allele showed evi-
dence of significant association with Caucasians.
Several previous studies reported that the ε2 allele is a
genetic risk factor for all-cause CKD [26] and related to
increased risk of ESRD. [27, 28] In contrast, the ε4 allele
may be associated with a lower risk of diabetic nephrop-
athy [29]. Furthermore, lipoprotein glomerulopathy, a
rare inherited renal disease characterized by proteinuria
Table 5 Demographic and laboratory characteristics of patients according to ADMA tertile
First tertile(0.12 - 0.54) (N = 199) Second tertile(0.55 - 0.79) (N = 206) Third tertile(0.80 - 4.91) (N = 207) P
Age (years) 62.37 ± 10.53 66.01 ± 11.95 65.64 ± 11.70 0.000**
Dialysis vintage (months) 2.48 ± 24.24 7.90 ± 1.48c 25.62 ± 1.92a,b 0.000**
Male 25 (21.6 %) 91 (78.4 %) 37 (19.7 %) 0.508***
Caucasian 31 (22.8 %) 105 (72.2 %) 51 (20.6 %) 0.440***
BMI (kg/cm2) 29.74 ± 5.55 29.11 ± 5.24 27.63 ± 13.43 0.000**
Waist circumference (cm) 99.46 ± 13.43 101.45 ± 11.40 101.88 ± 14.62 0.798*
Diabetes mellitus 15 (23.1 %) 50 (76.9 %) 32 (18.8 %) 0.895***
Metabolic syndrome 28 (19.4 %) 116 (80.6 %) 48 (17.8 %) 0.733***
Cardiovascular disease 66 (30.1 %) 77 (35.2 %) 76(34.7 %) 0.646***
o Cerebrovascular disease 0 (0.0 %) 20 (100.0 %) 13 (28.3 %) 0.073***
o Coronary disease 13 (29.5 %) 31 (70.5 %) 11 (16.9 %) 0.703***
o Peripheral vascular disease 22 (22.9 %) 35 (36.5 %) 39 (20.4 %) 0.697***
o Congestive heart failure 27 (34.2 %) 28 (35.4 %) 24 (30.4 %) 0.738***
Statin use 23 (21.9 %) 82 (78.1 %) 38 (19.4 %) 0.602***
Cholesterol(mM) 4.70 ± 1.08 4.45 ± 1.07c 4.59 ± 1.07a.b 0.000*
HDL-C(mM) 1.21 ± 0.34 1.05 ± 0.39 1.13 ± 0.36 a.b 0.000*
LDL-C(mM) 2,71 ± 0.92 2.53 ± 0.88 2.24 ± 2.24 a.b 0.000*
Triglycerides(mM) 1.99 ± 1.36 1.66 ± 1.14 1.84 ± 1.06 0.804**
Uric acid (mM) 0.36 ± 0.11 0.42 ± 0.12c 0.41 ± 0.10 b 0.000*
Creatinine(μM) 131.72 ± 81.33 845.10 ± 239.56c 947.65 ± 290.84a,b 0.000**
CRP (mg/dL) 0.50 ± 0.08 0.66 ± 0.21 0.50 ± 0.72 0.321**
*ANOVA, **Kruskal-Wallis-one way- ANOVA, ***Pearson chi-square
By post hoc Bonferroni test: a groups III and II, bgroups III and I, cgroups II and I
Table 6 ApoE genotypes and alleles among ADMA tertiles
First tertile(0.12 - 0.54) (N = 199) Second tertile(0.55 - 0.79) (N = 206) Third tertile(0.80 - 4.91) (N = 207) P*
ε3/ε2 19 (9.9 %) 21 (10.3 %) 16(7.8 %) NS
ε3/ε3 123 (64.4 %) 147 (72.4 %) 158 (77.5 %) NS
ε4/ε2 7 (3.7 %) 2 (1.0 %) 1 (0.5 %) NS
ε4/ε3 37 (19.4 %) 30 (14.8 %) 25 (12.3 %) NS
ε4/ε4 5 (0.8 %) 3 (0.5 %) 4 (0.7) NS
ε2 allele 26 (13.6 %) 23 (11.3 %) 17 (8.3 %) NS
ε3 allele 179 (93.7 %) 197 (97.0 %) 199 (97.5 %) NS
ε4 allele 49 (25.7 %) 35 (17.2 %) 29 (14.2 %) 0.011
Adjusted residual 2.9 −0.7 −2.1
*Pearson chi-square
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and progression to CKD, has a strong relation with mu-
tations in the ApoE gene [30]. An association between
ESRD and ApoE polymorphism has been found in some
but not all studies. Hubacek el al. found more carriers of
the ε2 allele in ESRD patients (15.9 %) than in controls
[28]. However, Roussos et al. [31] found that patients
with ESRD showed no difference in ε2, ε3 and ε4 distri-
bution compared with the control group. Feussner et al.
also failed to find an association between ε2 and ESRD.
[32] We did not find statistical differences between
groups stratified by renal function, analyzing allele and
genotype distribution.
When we accessed the relation between ADMA level
and ApoE allele frequency among those patients in RRT,
we observed that patients on hemodialysis and with the
highest ADMA levels exhibited a significantly lower
frequency of the ε4 allele when compared with that of
patients in the sum of first and second tertiles of ADMA.
This association remained significant even after correction
for confounding factors. An interrelationship of ADMA
and ApoE in atherogenesis was assessed in the work of
Jacobi et al., in which mice defficient in ApoE and
overexpressing DDAH showed reduced plaque formation
in the aorta. A functional analysis of aortic ring prepara-
tions revealed improved endothelial function in mice over-
expressing DDAH [33]. This association is interesting
because it provides the patient with potentially greater
endothelial dysfunction, represented by higher ADMA,
and risk of cardiovascular complications the potential pro-
tection associated with the absence of the ε4 allele.
Medina-Urrutiaet al. [34] showed that the presence of the
ε4 allele was associated with elevations in LDL-C, while
the presence of ε2 was associated with decreased levels of
LDL-C. Compared with individuals with the ε3/ε3 geno-
type, ε2 carriers have a 20 % lower risk of coronary heart
disease and ε4 carriers have a slightly higher risk [35]. A
recent study by our group in a cohort of hypertensive
patients with metabolic syndrome, revealed a higher
prevalence of CVD among ∈4 allele carriers [36]. On
the other hand, this association suggests that uremia
is capable of determining lower plasma ADMA levels
among ε4 allele carriers. ApoE ε4 allele expression
could be limited by the presence of certain clinical
variables, as can be seen in our study.
This study had some limitations. First, it was a
cross-sectional study. The results of a study com-
posed exclusively of hypertensive patients, conducted
at a single center, cannot be extrapolated to the gen-
eral population. It is descriptive and the mechanisms
underlying this association cannot be inferred here. A
greater number of participants in each renal function
group could have allowed us to determine if this
association between lower frequency of ApoE ε4 allele
with higher level of ADMA also occurs in earlier
stages of CKD. Genetic analysis methods (single
nucleotide polymorphism) have limitations in the
comprehension of the genotype - phenotype interface:
these methods do not enable the simultaneous analysis of
Fig. 1 Comparison of frequency of ApoE ε4 allele between ADMA
tertiles 3 and 1 in renal function groups
Table 7 Logistic regression analysis of the association between ApoE ε4 allele frequency and third ADMA tertile, among patients in
RRT
OR CI p
Adjusted for ApoEε4 allele 0.329 0.155 - 0.699 0.004
Adjusted for ApoEε4 allele, age 0.330 0.155 - 0.700 0.004
Adjusted for ApoEε4 allele, age, race 0.341 0.162 - 0.719 0.005
Adjusted for ApoEε4 allele, age, race, sex 0.321 0.148- 0.697 0.005
Adjusted for ApoEε4allele, age, race, sex, BMI 0.317 0.146- 0.689 0.004
Adjusted for ApoEε4allele, age, race, sex, BMI, DM 0.263 0.111- 0.623 0.002
Adjusted for ApoEε4allele, age, race, sex, BMI, DM, CVD 0.270 0.114- 0.638 0.003
Adjusted for ApoEε4allele, age, race sex, BMI, DM, CVD, CRP 0.271 0.114- 0.640 0.003
Adjusted for ApoEε4allele, age, race, sex, BMI, DM, CVD, CRP, LDL-C 0.283 0.118 - 0.680 0.005
Adjusted for ApoE E4allele, age, sex, BMI, DM, CVD, CRP, LDL-C, dialysis vintage 0.283 0.118- 0.681 0.005
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multiple genes, like in genome wide association, hamper-
ing the search for a genetic signature for polygenetic
diseases.
Conclusions
The presented results show, for the first time, that uremia
is capable of determining lower plasma ADMA levels in
hypertensive ε4 allele carriers. This association between
lower frequency of ApoE ε4 allele and higher ADMA
levels in ESRD may indicate a new way to approach
atherogenesis in the inflammatory state of uremia. Con-
firmation of such observations needs to be validated in a
longitudinal observation with a larger population study.
Methods
The study was approved by the Ethics and Research
Committee (no. 311.413/06.21.2013, Ministry of Health,
Brazil). All patients received relevant explanations and
signed Ethics and Research Committee Informed
Consent.
Six hundred twenty patients were stratified into 3
groups according to estimated GFR by CKD-EPI formula:
group I > 60 mL/min, group II ≤ 60 mL/min and > 15 mL/
min, and group III ≤ 15 mL/min or in hemodialysis. Exclu-
sion criteria were as follows: aged under 18 years, clinical
or laboratory suspicion of acute renal failure, pregnancy
and cancer.
Patient’s data were collected by clinical evaluation,
physical examination, file reviews and laboratory tests.
Presence of CVD was considered when identified in of-
fice or registry files: history of stroke, peripheral vascular
disease, coronary artery disease or CHF. [37] Identifica-
tion of DM was determined according to the American
Diabetes Association Guidelines [38].
Plasma concentrations of glucose, total cholesterol and
triglycerides were determined by automated enzymatic
assays. HDL was measured in serum by the homoge-
neous method after precipitation of VLDL and LDL with
phosphotungstate and magnesium ions, centrifugation
and measurement of the supernatant absorbance at
500 nm wavelength, following the manufacturer’s in-
structions. LDL was calculated according to the Friede-
wald equation. Renal function was assessed by plasma
urea level, measured by colorimetric-enzymatic assay
and by plasma creatinine level, determined by the Jaffé
method with calibration traceable to an isotope dilution
mass spectrometry reference measurement procedure
[39]. CRP was measured by ultrasensitive immunoturbi-
dimetry, following the manufacturer’s instructions.
Blood samples from subjects with ESRD undergoing
hemodialysis was always obtained immediately before
treatment.
ADMA levels
Plasma ADMA levels were measured by HPLC, as descri-
bedby Teerlinket al. [40] Briefly, samples were prepared as
follows: 200 μL of plasma containing EDTA or heparin
were transferred to an Eppendorf tube (1.5 mL), and
100 μL of internal standard solution (40 μM monomethy-
larginine) were then added. PBS was added to complete
the volume to 1 mL. This mixture was introduced into an
OASYS extraction cartridge (Waters) coupled to a vac-
uum system previously equilibrated with 1 mL of metha-
nol and 1 mL of deionized water. Next, the cartridge was
rinsed with 1 mL of 100 mM HCl, followed by 1 mL of
methanol, to elute neutral compounds and acids, and
elution was performed with 1 mL of ammonia/water/
methanol (10/40/50) solvent. The eluate recovered was
dried at 60 °C in a speed-vacuum system, and the residue
obtained was dissolved in 100 μL of water, followed by the
addition of 100 μL of ortho-phthaldialdehyde. After
15 min of reaction, the samples were transferred to appro-
priate HPLC vials.
We used a Symmetry C18 column (3.9 x 150 mm;
4 μm) coupled to a pre-column equilibrated with the same
stationary phase. The mobile phase A consisted of 50 mM
potassium phosphate buffer (pH 6.5) and mobile phase B
(acetonitrile/water; 1/1, v/v). Samples (20 μL) were sepa-
rated using an HPLC system with automatic injector.
Standard solutions containing arginine (25, 50, 75,
100 and 150 μM) and ADMA (0.25, 0.50, 1.00, 2.5,
5.0 μM) and 40 μM of internal standard solution
were extracted as described above to be injected be-
fore and after the injection of samples. The flow rate
was 1.1 mL/min.
The time interval between each injection was 30 min,
and fluorescence was measured at emission and excitation
wave lengths of 340 and 455 nm, respectively.
Analysis of ApoE gene polymorphisms
The sequence of 244 base pairs of the ApoE gene was
amplified by PCR, using the primers: sense 5’-TCCAAG-
GACCTGCAGGCGGCGCA-3’ and antisense 5’ACA-
GAATTCCGCCCCGGCCTGGTACACTGCCA-3’.
The PCR products were digested with the restriction
enzyme HhaI, and the fragments were separated by 10 %
polyacrylamide gel electrophoresis. Afterwards, the gel
was incubated with ethidium bromide (0.5 μL/mL) for
90 min at 120 V in 1xTBE solution, and the DNA frag-
ments were visualized with UV light. The ε2, ε3 and ε4
alleles were analyzed and the corresponding genotypes
determined.
Groups were analyzed and compared with regard to epi-
demiological, clinical and laboratory characteristics as well
as ApoE allele and genotype distribution. The prevalence
of different alleles and genotypes were analyzed in relation
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to race, where Hardy-Weinberg equilibrium was observed.
Plasma ADMA levels were compared on the basis of RRT
allocation ApoE polymorphism.
Statistical analysis
Results were expressed as mean ± SD or percentage. Com-
parisons of continuous variables among the three renal
function groups were carried out with ANOVA and
Kruskal-Wallis-one way-ANOVA, followed by post hoc
Bonferroni tests. Comparisons of frequency between
groups were performed using Pearson chi-square test.
Binary logistic regression analysis was used to test the as-
sociation between ApoE ε4 allele frequency and endothe-
lial dysfunction, in patients in RRT. The level of nullity
was fixed at 0,05 or 5 % for all tests.
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